{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:19:13Z","timestamp":1791472753251,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40264-025-01516-x","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:50:41Z","timestamp":1739292641000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Fracture Associated with Pregabalin or Mirogabalin Use: A Case-Case-Time-Control Study Based on Japanese Health Insurance Claims Data"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1253-7890","authenticated-orcid":false,"given":"Hinako","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0737","authenticated-orcid":false,"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-9427","authenticated-orcid":false,"given":"Satomi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-576X","authenticated-orcid":false,"given":"Kairi","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-0728","authenticated-orcid":false,"given":"Soichiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7490-5820","authenticated-orcid":false,"given":"Takayuki","family":"Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanp\u00e4\u00e4 M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02999.x.","journal-title":"Eur J Neurol"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrd.2018.42","volume":"17","author":"L Urquhart","year":"2018","unstructured":"Urquhart L. Top drugs and companies by sales in 2017. Nat Rev Drug Discov. 2018;17:232\u2013232. https:\/\/doi.org\/10.1038\/nrd.2018.42.","journal-title":"Nat Rev Drug Discov"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","volume":"178","author":"ME Johansen","year":"2018","unstructured":"Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178:292. https:\/\/doi.org\/10.1001\/jamainternmed.2017.7856.","journal-title":"JAMA Intern Med"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2018.12358","volume":"320","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017. JAMA. 2018;320:2149. https:\/\/doi.org\/10.1001\/jama.2018.12358.","journal-title":"JAMA"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","volume":"179","author":"CW Goodman","year":"2019","unstructured":"Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0086.","journal-title":"JAMA Intern Med"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79:463\u20138. https:\/\/doi.org\/10.1007\/s40265-019-01070-8.","journal-title":"Drugs"},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"EP Calandre","year":"2016","unstructured":"Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16:1263\u201377. https:\/\/doi.org\/10.1080\/14737175.2016.1202764.","journal-title":"Expert Rev Neurother"},{"key":"1516_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac205","author":"M Montero-Odasso","year":"2022","unstructured":"Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022. https:\/\/doi.org\/10.1093\/ageing\/afac205.","journal-title":"Age Ageing"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1681\/ASN.2018010096","volume":"29","author":"JH Ishida","year":"2018","unstructured":"Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29:1970\u20138. https:\/\/doi.org\/10.1681\/ASN.2018010096.","journal-title":"J Am Soc Nephrol"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1681\/ASN.2019090904","volume":"31","author":"C Vangala","year":"2020","unstructured":"Vangala C, Niu J, Montez-Rath ME, Yan J, Navaneethan SD, Naik AD, et al. Hip fracture risk among hemodialysis-dependent patients prescribed opioids and gabapentinoids. J Am Soc Nephrol. 2020;31:1325\u201334. https:\/\/doi.org\/10.1681\/ASN.2019090904.","journal-title":"J Am Soc Nephrol"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pds.4976","volume":"29","author":"Y Miyamoto","year":"2020","unstructured":"Miyamoto Y, Iwagami M, Aso S, Matsui H, Doi K, Yasunaga H. Pregabalin and injury: a nested case-control and case-crossover study. Pharmacoepidemiol Drug Saf. 2020;29:558\u201364. https:\/\/doi.org\/10.1002\/pds.4976.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","volume":"175","author":"D Bouhassira","year":"2019","unstructured":"Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175:16\u201325. https:\/\/doi.org\/10.1016\/j.neurol.2018.09.016.","journal-title":"Rev Neurol (Paris)."},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kww079","volume":"184","author":"J Hallas","year":"2016","unstructured":"Hallas J, Potteg\u00e5rd A, Wang S, Schneeweiss S, Gagne JJ. Persistent user bias in case-crossover studies in pharmacoepidemiology. Am J Epidemiol. 2016;184:761\u20139. https:\/\/doi.org\/10.1093\/aje\/kww079.","journal-title":"Am J Epidemiol"},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/aje\/kwu162","volume":"180","author":"SV Wang","year":"2014","unstructured":"Wang SV, Schneeweiss S, Maclure M, Gagne JJ. \u201cFirst-wave\u201d bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014;180:636\u201344. https:\/\/doi.org\/10.1093\/aje\/kwu162.","journal-title":"Am J Epidemiol"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138. https:\/\/doi.org\/10.31662\/jmaj.2021-0189.","journal-title":"JMA J."},{"key":"1516_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07255-6","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K. Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int. 2024. https:\/\/doi.org\/10.1007\/s00198-024-07255-6.","journal-title":"Osteoporos Int"},{"key":"1516_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwae448","author":"T Okura","year":"2024","unstructured":"Okura T, Tanaka-Mizuno S, Fukasawa T, Yoshida S, Kawakami K. Assessing the risk of gastrointestinal perforation associated with COVID-19: a self-controlled case series study. Am J Epidemiol. 2024. https:\/\/doi.org\/10.1093\/aje\/kwae448.","journal-title":"Am J Epidemiol"},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/ede.0b013e31821d09cd","volume":"22","author":"S Wang","year":"2011","unstructured":"Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, et al. Future cases as present controls to adjust for exposure trend bias in case-only studies. Epidemiology. 2011;22:568\u201374. https:\/\/doi.org\/10.1097\/ede.0b013e31821d09cd.","journal-title":"Epidemiology"},{"key":"1516_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2136","author":"W-C Huang","year":"2023","unstructured":"Huang W-C, Lai EC-C. Future-case control crossover analysis for adjusting bias in case crossover studies. BMJ. 2023. https:\/\/doi.org\/10.1136\/bmj.p2136.","journal-title":"BMJ"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","volume":"133","author":"M Maclure","year":"1991","unstructured":"Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144\u201353. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115853.","journal-title":"Am J Epidemiol"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00001648-199505000-00010","volume":"6","author":"S Suissa","year":"1995","unstructured":"Suissa S. The case-time-control design. Epidemiology. 1995;6:248\u201353. https:\/\/doi.org\/10.1097\/00001648-199505000-00010.","journal-title":"Epidemiology"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jval.2019.09.2746","volume":"23","author":"Y-H Dong","year":"2020","unstructured":"Dong Y-H, Wang SV, Gagne JJ, Wu L-C, Chang C-H. Comparison of different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk of heart failure as an example. Value Health. 2020;23:217\u201326. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2746.","journal-title":"Value Health."},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/phar.2761","volume":"43","author":"K Ri","year":"2023","unstructured":"Ri K, Fukasawa T, Yoshida S, Takeuchi M, Kawakami K. Risk of parkinsonism and related movement disorders with gabapentinoids or tramadol: a case-crossover study. Pharmacotherapy. 2023;43:136\u201344. https:\/\/doi.org\/10.1002\/phar.2761.","journal-title":"Pharmacotherapy"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/ije\/dyu081","volume":"43","author":"MA Mittleman","year":"2014","unstructured":"Mittleman MA, Mostofsky E. Exchangeability in the case-crossover design. Int J Epidemiol. 2014;43:1645\u201355. https:\/\/doi.org\/10.1093\/ije\/dyu081.","journal-title":"Int J Epidemiol"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1186\/s12889-020-09920-x","volume":"20","author":"P Zaninotto","year":"2020","unstructured":"Zaninotto P, Huang YT, Di Gessa G, Abell J, Lassale C, Steptoe A. Polypharmacy is a risk factor for hospital admission due to a fall: evidence from the English Longitudinal Study of Ageing. BMC Public Health. 2020;20:1804. https:\/\/doi.org\/10.1186\/s12889-020-09920-x.","journal-title":"BMC Public Health"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ageing\/afaa249","volume":"50","author":"LJ Seppala","year":"2021","unstructured":"Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbi\u0144ska K, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing. 2021;50:1189\u201399. https:\/\/doi.org\/10.1093\/ageing\/afaa249.","journal-title":"Age Ageing"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12877-024-04887-5","volume":"24","author":"N Mielke","year":"2024","unstructured":"Mielke N, Barghouth MH, Fietz A-K, Villain C, Bothe T, Ebert N, et al. Effect modification of polypharmacy on incident frailty by chronic kidney disease in older adults. BMC Geriatr. 2024;24:335. https:\/\/doi.org\/10.1186\/s12877-024-04887-5.","journal-title":"BMC Geriatr"},{"key":"1516_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5850","volume":"33","author":"J Hallas","year":"2024","unstructured":"Hallas J, Maclure M. Use of point-in-time or window approach in the case-crossover design, implications for pharmacoepidemiologic research using registries. Pharmacoepidemiol Drug Saf. 2024;33: e5850. https:\/\/doi.org\/10.1002\/pds.5850.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/aje\/kwad104","volume":"192","author":"K Kubota","year":"2023","unstructured":"Kubota K, Kelly T-L. Bias due to within-subject exposure dependency with or without bias due to lack of pairwise exchangeability when exposure is chronic in case-crossover and case-time-control studies: a simulation study. Am J Epidemiol. 2023;192:1701\u201311. https:\/\/doi.org\/10.1093\/aje\/kwad104.","journal-title":"Am J Epidemiol"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jama.2023.26942","volume":"331","author":"PB Leung","year":"2024","unstructured":"Leung PB, Alexander JT, Ouchida KE. Falls prevention for older adults. JAMA. 2024;331:1409\u201310. https:\/\/doi.org\/10.1001\/jama.2023.26942.","journal-title":"JAMA"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01516-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:37:17Z","timestamp":1744220237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01516-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01516-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"16 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Toshiki Fukasawa has been employed by the Department of Digital Health and Epidemiology, an Industry-Academia Collaboration Course supported by Eisai Co., Ltd. and Kyowa Kirin Co., Ltd., and has received consulting fees from Real World Data Co., Ltd. and JMDC Inc. Satomi Yoshida has received consulting fees from Toyota Konpon Research Institute Inc. Kairi Ri has been employed by Datack Inc. Koji Kawakami receives research funds from AstraZeneca K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., AIS Co., Ltd., JMDC Inc., Santen Pharmaceutical Co., Ltd., Shin Nippon Biomedical Laboratories Ltd., and Ubicom Holdings Inc.; executive compensation from Cancer Intelligence Care Systems, Inc.; and honoraria from Pharma Business Academy and Taisho Pharmaceutical Co., Ltd. The other authors report no conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data cannot be shared publicly due to the contract with DeSC Healthcare, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (approval number: R4118-1).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the data were anonymized, informed consent was not required in accordance with Japanese ethical guidelines.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Code is available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Hinako Wakabayashi: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing\u2014original draft, Writing\u2014review and editing. Toshiki Fukasawa: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Visualization, Writing\u2014original draft, Writing\u2014review and editing. Satomi Yoshida: Conceptualization, Writing\u2014review and editing. Kairi Ri: Formal analysis, Writing\u2014review and editing. Soichiro Masuda: Methodology, Writing\u2014review and editing. Takayuki Anno: Methodology, Writing\u2014review and editing. Koji Kawakami: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing\u2014review and editing.\u00a0All authors read and approved the final version.\u00a0","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}